Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Spinal Cord Inflammation Seen to Change Brain Connectivity on fMRIs

Inflammatory episodes in the spinal cord of people with neuromyelitis optica spectrum disorder (NMOSD) resulted in changes in functional connectivity in the brain, an imaging study shows. Functional connectivity refers to the correlation between brain signals over time that reflects functional connections between two or more brain regions. Reduced…

OCT Retinal Imaging May Help Support Diagnosis of NMOSD

Measuring the retinal nerve layers by a non-invasive tool called optical coherence tomography may help to diagnose neuromyelitis optica spectrum disorder (NMOSD), especially in those who test negative for disease-related antibodies, according to a new study. Researchers found that nerve layers in the retina of people with NMOSD…

CoronaVac Leads to Rare Severe Case of NMOSD in Elderly Woman

The CoronaVac vaccine, which contains inactivated SARS-CoV-2, the virus that causes COVID-19, led to a severe case of late-onset neuromyelitis optica spectrum disorder (NMOSD) in a 70-year-old woman. The unique case was described in an article, “Fulminant neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccination: A…

Rituximab Clears NMOSD-causing Antibodies From Lymph Nodes

Self-reactive antibodies that cause most cases of neuromyelitis optica spectrum disorder (NMOSD) are released directly from immune B-cells in lymph nodes as opposed to cells in the bloodstream, a study has discovered. These findings implicate ongoing lymph node activity as the main driver of disease-causing antibody production in NMOSD.

Uplizna Reduces NMOSD Attack Severity, Analysis Shows

Uplizna (inebilizumab-cdon) effectively reduced the severity of attacks in people with neuromyelitis optica spectrum disorder (NMOSD) who continued to experience attacks after being treated with the therapy during the N-MOmentum Phase 2/3 clinical trial, recent data analysis shows. The data also demonstrated lower levels of key disease-related biomarkers,…

Claims Analysis Shows High Comorbidities, Care Costs for Patients

People with neuromyelitis optica spectrum disorder (NMOSD) experience a high prevalence of co-existing conditions, or comorbidities, which are associated with much higher healthcare costs, a claims analysis demonstrated. In particular, pharmacy costs for NMOSD patients with any comorbidity were “significantly higher” than for those with no co-existing conditions: a…

Analysis: Uplizna Provides Long-term NMOSD Attack Prevention

Uplizna (inebilizumab-cdon) safely prevented autoimmune attacks in 83% of people with neuromyelitis optica spectrum disorder (NMOSD) who received the treatment for four or more years, data from the N-MOmentum Phase 2/3 clinical trial show. Among those who experienced relapses, most did so during the first year of treatment.

NMOSD Relapses Common, Increase Healthcare Costs in US

Almost half of U.S. patients with neuromyelitis optica spectrum disorder (NMOSD) experienced relapses over a period of two years, according to an analysis of a large healthcare claims database. Such relapses — which lasted on average nearly 13 days — were treated more often with outpatient rather than hospital…